Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Usana Health SciencesUSNA +1.31%63 EV-to-EBIT is 62.03 as of Aug. 06, 2026, which is 624% above its 10-year median of 8.57. GuruFocus rates USNA with a GF Score™ of 63/100 and a GF Value™ of $41.48 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,555 Consumer Packaged Goods companies, Usana Health Sciences ranks worse than 92.48% on this metric.
Usana Health Sciences (NYSE:USNA) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Usana Health Sciences's Enterprise Value for the quarter that ended in Mar. 2026 was $224.9 Mil.
Usana Health Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Usana Health Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Usana Health Sciences EV-to-EBIT vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Usana Health Sciences's EV-to-EBIT falls into.
Usana Health Sciences's current Enterprise Value is $182.9 Mil.
Usana Health Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Usana Health Sciences (USNA) has a EV-to-EBIT of 62.03 as of Aug. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Usana Health Sciences and its competitors. This is 624% above median its historical median of 8.57. Over the past decade, Usana Health Sciences' EV-to-EBIT has ranged from 2.93 to 62.03. According to the industry distribution chart, Usana Health Sciences ranks #1438 out of 1555 companies in the Consumer Packaged Goods industry, placing it in the top 92.5%.
Is Usana Health Sciences' EV-to-EBIT too high?
Usana Health Sciences' current EV-to-EBIT of 62.03 is 624% above median its 10-year median of 8.57. Over the past 10 years, this metric has ranged from a low of 2.93 to a high of 62.03. The Consumer Packaged Goods industry median EV-to-EBIT is 12.07. Usana Health Sciences' value of 62.03 is 413.9% above this industry median. Based on the distribution chart, Usana Health Sciences ranks #1438 out of 1555 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Usana Health Sciences has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Usana Health Sciences' EV-to-EBIT compare to ENHA and NATR?
According to the Consumer Packaged Goods industry distribution chart, Usana Health Sciences ranks #1438 out of 1555 companies for EV-to-EBIT. This places Usana Health Sciences in the lower half of its industry. The industry median EV-to-EBIT is 12.07. Usana Health Sciences' value of 62.03 is 413.9% above this benchmark. Historically, Usana Health Sciences' own EV-to-EBIT has ranged from 2.93 to 62.03 over the past decade. While the company's 10-year median is 8.57 vs. the industry median of 12.07, Usana Health Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Consumer Packaged Goods company?
The median EV-to-EBIT among Consumer Packaged Goods companies is 12.07, based on 1,555 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Usana Health Sciences's current EV-to-EBIT of 62.03 is 413.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Usana Health Sciences and its competitors. For the Consumer Packaged Goods industry, the median EV-to-EBIT is 12.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Usana Health Sciences's current EV-to-EBIT is 62.03, which is 624% above median its own 10-year median of 8.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Usana Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Usana Health Sciences (USNA) is currently considered Possible Value Trap. The stock's GF Value™ is $41.48, compared to a current price of $15.19 — trading 63.4% below its estimated fair value. The current EV-to-EBIT is 62.03, which is 624% above median its 10-year median of 8.57 and 413.9% above the Consumer Packaged Goods industry median of 12.07. Usana Health Sciences' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Usana Health Sciences (USNA), the current EV-to-EBIT is 62.03 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Usana Health Sciences (USNA) Overvalued in 2026?
Based on GuruFocus' analysis, Usana Health Sciences stock appears to be undervalued.
The current stock price of $15.19 is trading 63.4% below its estimated GF Value™ of $41.48.
GuruFocus considers Usana Health Sciences to be Possible Value Trap.
Key valuation signals for USNA:
EV-to-EBIT: 62.03 (624% above median its 10-year median of 8.57)
GF Value™: $41.48 vs. price of $15.19 (63.4% below fair value)
Industry Position: 413.9% above the Consumer Packaged Goods median (#1438 of 1555)
No single metric tells the full story. See the USNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
63GF Score
Get the complete analysis for USNA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
USNA has been successfully added to your 
